MapLight Halts Discovery Work as ADCT Weighs Zynlonta's Fate

MapLight Therapeutics has paused its preclinical and discovery programs to concentrate resources on lead candidate ML-007C-MA in schizophrenia and Alzheimer's disease psychosis, while ADC Therapeutics (ADCT) is weighing options for its marketed lymphoma drug Zynlonta; ADCT last traded at 1.01, down 3.81% on Aug. 14, 2026.

Two very different biotechs made the same underlying admission this week: there is no longer enough capital to do everything. MapLight Therapeutics said it is pausing its preclinical and discovery research to funnel resources into its lead asset, ML-007C-MA, being developed for schizophrenia and psychosis associated with Alzheimer's disease. Separately, ADC Therapeutics (NYSE: ADCT) is weighing what to do with Zynlonta, its marketed antibody-drug conjugate for lymphoma, according to Endpoints News.

Neither move involves a failed trial or a regulatory rejection. Both are allocation decisions — the kind that surface when the cost of capital is high enough that a second and third program stop looking like optionality and start looking like a drag.

What pausing discovery actually costs a biotech

Discovery and preclinical work is the part of a drug pipeline that generates future clinical candidates. It is also the part with no near-term catalyst attached, which makes it the first place a management team looks when it needs to extend cash runway without touching the asset investors are actually underwriting.

By pausing that layer, MapLight is converting itself, at least temporarily, into something close to a single-asset company. ML-007C-MA is a muscarinic-targeted approach — the mechanism class that has drawn intense attention in neuropsychiatry after regulators accepted muscarinic agonism as a genuinely new way to treat schizophrenia, distinct from the dopamine-blocking antipsychotics that have dominated for decades. Adding Alzheimer's disease psychosis as a second indication widens the commercial case considerably, because that population is large, largely underserved and skews toward patients who tolerate conventional antipsychotics poorly.

The trade-off is concentration risk. A company with discovery running in the background has a story to tell if the lead asset stumbles. A company that has switched that engine off does not. Restarting discovery is also not free: bench scientists who are let go or reassigned do not reassemble on demand, and chemistry programs lose momentum when they go dormant.

Zynlonta is a marketed drug, which changes the calculus

ADC Therapeutics' situation is structurally different and, in some ways, harder. Zynlonta is not a preclinical line item — it is an approved, commercialized antibody-drug conjugate, meaning a targeting antibody chemically linked to a cytotoxic payload that is delivered preferentially to tumor cells. Commercial infrastructure — field sales, market access, distribution, medical affairs — is expensive and, unlike a discovery group, cannot be quietly paused without immediately hitting revenue.

"Considering what to do" with a marketed asset generally narrows to a short list: sell it outright, license it regionally or globally to a partner with existing oncology reach, restructure the commercial effort to a smaller footprint, or keep spending and push for label expansion. Each option trades near-term cash against long-term upside. An outright sale or royalty-bearing license converts an operating expense into inbound cash, but caps participation if the drug grows. Retrenching the sales force preserves ownership and slows the burn, at the cost of prescription momentum.

Where ADCT's shares sit going into the decision

The market is not pricing in much patience. ADC Therapeutics closed at 1.01 on Friday, Aug. 14, 2026, down 3.81% from the prior close of 1.05, having traded between 1.00 and 1.04 during the session. That is a stock changing hands around a dollar — territory where the equity itself becomes a constraint on strategy, because raising money by issuing shares at that level is heavily dilutive and any exchange listing standard tied to minimum price becomes a live administrative concern.

The move came on an otherwise quiet tape. The S&P 500 tracker (NYSEARCA: SPY) closed at $776.34, down 0.20% from $777.88; the Nasdaq 100 fund (NASDAQ: QQQ) finished at $731.07, off 0.14%; and the Dow tracker (NYSEARCA: DIA) closed at $536.80, down 0.21%. Broad indices moved fractionally. ADCT moved multiples of that, which is what happens when a small-cap's valuation hinges on a single strategic question rather than on macro.

The funding backdrop behind both decisions

ADCT moved multiples of that, which is what happens when a small-cap's valuation hinges on a single strategic question rather than on macro.

These are not isolated stories. A pattern has been running through the sector: companies with one credible clinical asset and several speculative ones are choosing the credible one, and companies with a marketed drug that has not scaled fast enough are asking whether someone else should own the commercial job. It is a shift from breadth to depth, driven less by science than by the price of money.

For MapLight, a private-company decision, the pause buys clinical runway and sharpens the narrative for whoever writes the next check — a crossover investor, a partner, or eventually public markets. Single-asset companies can raise capital; they simply have to raise it on the strength of one data set.

For ADC Therapeutics, a public company trading near a dollar, the calculus is more urgent. The outcome of the Zynlonta review is likely to be the single biggest determinant of the equity story from here, more than any pipeline update.

What to watch from here

The shape of MapLight's ML-007C-MA program. Whether the schizophrenia and Alzheimer's psychosis indications advance in parallel or sequentially tells you how much cash the pause actually freed up.
Any Zynlonta transaction structure. A regional license, a global out-license and an asset sale imply very different views of the drug's ceiling — and very different cash profiles for ADC Therapeutics.
ADCT's cost base. If the review lands on retrenchment rather than divestiture, the tell will be the size of the commercial organization supporting the drug.
Listing mechanics. At roughly a dollar per share, share-price maintenance and financing capacity become operational issues, not just market chatter.
Whether peers follow. Two prioritization announcements in one news cycle is a coincidence. A steady stream of them is a funding environment.

The common thread is that neither company is reacting to bad science. Both are reacting to arithmetic. In a sector where the default posture for two decades was to build optionality and fund it with cheap equity, the new discipline is to identify the one thing that can carry the company and stop paying for the rest. MapLight has named its one thing. ADC Therapeutics is still deciding whether Zynlonta is best owned by ADC Therapeutics.

Key facts

ADCT last close: 1.01, -3.81%, as of 8:00 p.m. GMT Aug. 14, 2026
MapLight action: Paused preclinical and discovery work
Lead candidate: ML-007C-MA, for schizophrenia and Alzheimer's disease psychosis
ADC Therapeutics review: Weighing options for marketed lymphoma ADC Zynlonta

Frequently asked questions

What did MapLight Therapeutics announce?

MapLight Therapeutics said it is pausing its preclinical and discovery research programs and redirecting resources toward its lead clinical candidate, ML-007C-MA. That asset is being developed for schizophrenia and for psychosis associated with Alzheimer's disease. The move concentrates the company's spending on a single lead program rather than maintaining a broader early-stage pipeline.

What is ADC Therapeutics deciding about Zynlonta?

ADC Therapeutics is considering what to do with Zynlonta, its approved antibody-drug conjugate for lymphoma. The company has not stated an outcome. In practice, options for a marketed drug typically include selling the asset, licensing it to a partner with existing oncology commercial reach, shrinking the sales and marketing footprint, or continuing to invest in label expansion.

Where did ADCT shares last trade?

ADC Therapeutics closed at 1.01 on Friday, Aug. 14, 2026, a decline of 3.81% from the prior close of 1.05. The session range was 1.00 to 1.04. Markets were closed at the time of the quote, so that figure represents the most recent traded price rather than a live one.

What is an antibody-drug conjugate?

An antibody-drug conjugate, or ADC, pairs a targeting antibody with a potent cell-killing payload through a chemical linker. The antibody seeks out a marker found on tumor cells, delivering the toxin more selectively than traditional chemotherapy. Zynlonta, ADC Therapeutics' approved lymphoma treatment, is built on that approach.

Why do biotechs pause discovery research first?

Discovery and preclinical work generates future candidates but produces no near-term clinical or regulatory catalysts. That makes it the easiest line to cut when a company needs to extend its cash runway without touching the program investors are backing. The cost is concentration risk: if the lead asset fails, there is no back-up story ready.

How did the broad market perform the same day?

Major index trackers were fractionally lower on Aug. 14, 2026. The S&P 500 fund SPY closed at $776.34, down 0.20%. The Nasdaq 100 fund QQQ closed at $731.07, down 0.14%. The Dow tracker DIA finished at $536.80, down 0.21%. ADCT's decline was far larger than any index move that session.

Sources

MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta — Endpoints News

Photo: Edward Jenner · Pexels Licence — source